Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(4-(morpholinomethyl)benzoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1364712-01-5

Post Buying Request

1364712-01-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(4-(morpholinomethyl)benzoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

    Cas No: 1364712-01-5

  • Need to discuss

  • No requirement

  • Adequate

  • Chemvon Biotechnology Co. Ltd.
  • Contact Supplier
  • (8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-((E)-1-(4-(morpholinomethyl)benzoyloxyimino)ethyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one

    Cas No: 1364712-01-5

  • Need to discuss

  • No requirement

  • Adequate

  • Ningbo Syntame Biotech Co.,Ltd
  • Contact Supplier

1364712-01-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1364712-01-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,4,7,1 and 2 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1364712-01:
(9*1)+(8*3)+(7*6)+(6*4)+(5*7)+(4*1)+(3*2)+(2*0)+(1*1)=145
145 % 10 = 5
So 1364712-01-5 is a valid CAS Registry Number.

1364712-01-5Downstream Products

1364712-01-5Relevant articles and documents

Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury

Guthrie, David B.,Stein, Donald G.,Liotta, Dennis C.,Lockwood, Mark A.,Sayeed, Iqbal,Atif, Fahim,Arrendale, Richard F.,Reddy, G. Prabhakar,Evers, Taylor J.,Marengo, Jose R.,Howard, Randy B.,Culver, Deborah G.,Natchus, Michael G.

, p. 362 - 366 (2012)

After more than 30 years of research and 30 failed clinical trials with as many different treatments, progesterone is the first agent to demonstrate robust clinical efficacy as a treatment for traumatic brain injuries. It is currently being investigated in two, independent phase III clinical trials in hospital settings; however, it presents a formidable solubility challenge that has so far prevented the identification of a formulation that would be suitable for emergency field response use or battlefield situations. Accordingly, we have designed and tested a novel series of water-soluble analogues that address this critical need. We report here the synthesis of C-20 oxime conjugates of progesterone as therapeutic agents for traumatic brain injuries with comparable efficacy in animal models of traumatic brain injury and improved solubility and pharmacokinetic profiles. Pharmacodynamic analysis reveals that a nonprogesterone steroidal analogue may be primarily responsible for the observed activity.

PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO

-

Paragraph 00386; 00387, (2015/02/25)

This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or s

PROGESTERONE ANALOGS AND USES RELATED THERETO

-

Paragraph 0288-0289, (2013/08/28)

This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1364712-01-5